

**From:** Prof. Philippe Gillery – IFCC SD Chair

**Date:** November 24<sup>th</sup>, 2022

**Ref:** 8.2.23 Call for Nominations for Membership of Committee on Traceability in Laboratory Medicine (C-TLM)

## Scientific Division (SD)

### Chair

#### Prof. Philippe GILLERY

Service de Biochimie - Pharmacologie  
- Toxicologie  
Pôle de Biologie Médicale et  
Pathologie  
CHU de Reims  
Pôle de Biologie Territoriale  
51092 Reims Cedex - FRANCE  
E-mail: [pgillery@chu-reims.fr](mailto:pgillery@chu-reims.fr)

### Vice-Chair

#### Prof. Christa M. COBBAERT

Clinical Chemist  
Head of the Department of Clinical Chemistry  
Leiden University Medical Center  
2300 RC Leiden – THE NETHERLANDS  
E-mail: [C.M.Cobbaert@lumc.nl](mailto:C.M.Cobbaert@lumc.nl)

### Secretary

#### Prof. Garry JOHN

Department of Clinical Biochemistry and  
Immunology  
Norfolk and Norwich University Hospital  
Norwich NR4 7UY - UK  
E-mail: [g.john@nhs.net](mailto:g.john@nhs.net)

### Members

#### Dr. Barnali DAS

Lead Consultant, Biochemistry & Immunology  
Kokilaben Dhirubhai Ambani Hospital &  
Medical Research Institute,  
Mumbai-400053 - INDIA  
E-mail: [drbarnalid@gmail.com](mailto:drbarnalid@gmail.com)

#### Dr. Konstantinos MAKRI

Clinical Biochemist  
Clinical Biochemistry Department  
KAT General Hospital  
Kifissia, Athens - GREECE  
E-mail: [kostas.makris.km@gmail.com](mailto:kostas.makris.km@gmail.com)

#### Prof. Mario PLEBANI

Full Professor of Clinical Biochemistry and  
Clinical Molecular Biology  
Chief Department of Laboratory Medicine  
University Hospital – Padova  
Dean of the Medical School  
University of Padova – ITALY  
E-mail: [mario.plebani@unipd.it](mailto:mario.plebani@unipd.it)

### Corporate Representative

#### Dr. Michael ROTTMANN

Roche Diagnostics GmbH  
Director Assay Development  
Indication: Thyroid, Sepsis, RA, Growth Centralised  
and Point of Care solutions  
82377 Penzberg - GERMANY  
e-mail: [michael.rottmann@roche.com](mailto:michael.rottmann@roche.com)

### Bureau International des Poids et

### Mesures

#### BIPM Observer

#### Dr. Ralf D. JOSEPHS

Principal Chemist  
Pavillon de Breteuil  
92312 Sèvres Cedex - FRANCE  
E-mail: [ralf.josephs@bipm.org](mailto:ralf.josephs@bipm.org)

### European Commission –

#### JRC Observer

#### Dr. Liesbet DEPREZ

Project Officer  
Directorate General Joint Research Centre  
Reference Materials Unit  
2440 Geel – BELGIUM  
E-mail: [Liesbet.deprez@ec.europa.eu](mailto:Liesbet.deprez@ec.europa.eu)

### ICHCLR Observer

#### Prof. Ian S. YOUNG

Professor of Medicine  
Queen's University Belfast  
The Center for Public Health  
1st floor - ICS B block  
Royal Victoria Hospital  
BT12 6BJ - Belfast - UK  
E-mail: [I.Young@qub.ac.uk](mailto:I.Young@qub.ac.uk)

### JCTLM Consultant

#### Dr. Greg MILLER

Professor of Pathology  
Co-Director of Clinical Chemistry  
Director of Pathology Information Systems  
Virginia Commonwealth University Health System  
Richmond, VA 23298-0286 - USA  
Email: [greg.miller@vcuhealth.org](mailto:greg.miller@vcuhealth.org)

### NIBSC Consultant

#### Dr. Chris BURNS PhD

Head, Biotherapeutics Division  
National Institute for Biological Standards and  
Control - A Centre of the MHR  
Hertfordshire, EN6 3QG, UK  
E-mail: [Chris.Burns@nibsc.org](mailto:Chris.Burns@nibsc.org)

### NIFDC Observer

#### Dr. Yang Zhen

Deputy Director General  
National Institutes for Food and Drug Controls  
(NIFDC) - P.R. CHINA  
E-mail: [yangzhen@nifdc.org.cn](mailto:yangzhen@nifdc.org.cn)

### NIST Consultant

#### Dr. Karen W. PHINNEY

Leader, Bioanalytical Science Group  
Biomolecular Measurement Division  
National Institute of Standards  
and Technology (NIST)  
Gaithersburg, MD 20899-8314 - USA  
E-mail: [karen.phinney@nist.gov](mailto:karen.phinney@nist.gov)

**To:** IFCC Full Member Societies' National Representatives  
IFCC Affiliate Societies' Representatives  
IFCC Corporate Members' Representatives

Dear Colleagues,

In 2004, IFCC established a Committee on Traceability in Laboratory Medicine (C-TLM). Since then, the Committee has provided IFCC with high level expertise in the specific area of metrological traceability and standardization. The Committee, under the Chairmanship of Dr. Anja Kessler, intends to replace two members who have completed their term of office.

The terms of reference and current projects of the C-TLM are as follows:

### Terms of Reference

- To support activities regarding Traceability in Laboratory Medicine, permitting IFCC to continue its international role in this area and providing an operating link between the SD and the WGs of the Joint Committee on Traceability in Laboratory Medicine (JCTLM), concerning identification of reference measurement procedures, reference materials and reference laboratories.
- To support reference laboratories in the context of complete reference systems (accepted reference measurement procedures of higher order, reference materials, and reference laboratories) by establishing an External Quality Assessment Scheme (EQAS) for reference laboratories in order to monitor their competence.
- To promote establishment and maintenance of IFCC reference laboratory networks for clinically relevant measurands (e.g. the IFCC HbA1c network).

### Current Projects

- Organization of IFCC RELA surveys for calibration laboratories and candidate calibration laboratories

Information on the current composition of the C-TLM and its activities are available on the IFCC Website, at following link: <http://www.ifcc.org/ifcc-scientific-division/sd-committees/c-tlm/>. More specific information can be obtained directly from Dr. Anja Kessler - [a.kessler@spmd-rfb.de](mailto:a.kessler@spmd-rfb.de).


Nominations should be sent directly to the IFCC Office ([paola.bramati@ifcc.org](mailto:paola.bramati@ifcc.org)) by using the enclosed application form, **before December 20<sup>th</sup>, 2022**.

We would particularly welcome applications from young scientists and candidates with experience in standardisation and setting up reference measurement systems, although all applications will be given careful consideration.

Following approval, the candidates will be appointed for a three-year term (commencing in January 2023). A second three-year term is allowed following satisfactory review at the end of the first term by the Scientific Division Executive Committee following consultation with the C-TLM Chairman.

Yours sincerely

Prof. Philippe Gillery, MD, PhD



Chair IFCC Scientific Division